title: A 100-kDa protein tyrosine phosphorylation is concurrent with beta 1 integrin-mediated morphological differentiation in neuroblastoma and small cell lung cancer cells.
abstract: IMR32, a neuroblastoma cell line, and CADO LC6, a small cell lung cancer (SCLC) cell line, extended neurite-like processes when cultured on fibronectin (FN)-coated surfaces or cultured in a serum-free medium. Monoclonal antibodies against the integrin beta 1 subunit inhibited this process formation, suggesting that their morphological change is initiated by beta 1 integrin-dependent signal transduction to the cell interior. Anti-phosphorylation level of a 100-kDa protein, but not 125-kDa focal adhesion kindase, correlated well with the morphological change in both cell lines. This 100-kDa protein phosphorylation did not accompany FN-induced morphological changes in NIH 3T3 fibroblasts or A549 adenocarcinoma cells. These findings suggest that neuroblastoma and SCLC may share beta 1 integrin-mediated signaling events distinct from nonneuronal cells.
authors.affiliation: Department of Medicine III, Osaka University Medical School, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Tachibana
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: Y
authors.initials: Y
authors.lastname: Tanio
authors.forename: S
authors.initials: S
authors.lastname: Hosoe
authors.forename: T
authors.initials: T
authors.lastname: Sakuma
authors.forename: T
authors.initials: T
authors.lastname: Osaki
authors.forename: K
authors.initials: K
authors.lastname: Ueno
authors.forename: T
authors.initials: T
authors.lastname: Kumagai
authors.forename: T
authors.initials: T
authors.lastname: Kijima
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
mesh_terms: D000230:Adenocarcinoma; D016227:Benzoquinones; D015153:Blotting, Western; D018288:Carcinoma, Small Cell / Q000473:pathology*; D002448:Cell Adhesion / Q000502:physiology; D015815:Cell Adhesion Molecules / Q000378:metabolism; D002454:Cell Differentiation / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; D006801:Humans; D019012:Integrin beta1 / Q000494:pharmacology*; D047029:Lactams, Macrocyclic; D008175:Lung Neoplasms; D009447:Neuroblastoma / Q000473:pathology*; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011809:Quinones / Q000494:pharmacology; D011972:Receptor, Insulin / Q000378:metabolism; D017828:Rifabutin / Q000031:analogs & derivatives; D015398:Signal Transduction / Q000502:physiology*; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D014443:Tyrosine / Q000378:metabolism*
chemical_list: D016227:Benzoquinones; D015815:Cell Adhesion Molecules; D004791:Enzyme Inhibitors; D019012:Integrin beta1; D047029:Lactams, Macrocyclic; D011809:Quinones; D017828:Rifabutin; D014443:Tyrosine; C020754:herbimycin; D011505:Protein-Tyrosine Kinases; D011972:Receptor, Insulin; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; C496050:PTK2 protein, human